Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5717524 | 0.86 | KDM4E (0.54) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL31324205 | 0.81 | KDM4E (0.81) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL20424627 | 0.79 | HPGD (0.68) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL30639791 | 0.79 | HPGD (0.68) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL17444602 | 0.79 | KDM4E (0.70) | KDM4EMAPTALDH1A1HPGDMEN1 | |
| SCHEMBL5023941 | 0.78 | MAPT (0.57) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL14389440 | 0.77 | KDM4E (0.71) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL3995101 | 0.77 | THRB (0.56) | THRBAKR1C2 | |
| SCHEMBL3924708 | 0.77 | THRB (0.54) | KDM4EALDH1A1HPGDTHRBPPARG | |
| SCHEMBL1913689 | 0.76 | MAPT (0.51) | KDM4EMAPTALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643983-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9139586-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-01 | — | — | US | disclosed |
| US-8697687-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130012500-A1 | ORGANIC COMPOUNDS | BHALAY GURDIP (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2011-09-29 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| CN-1492874-A | Macrolide antibiotics | — | 2004-04-28 | — | — | CN | disclosed |
| EP-0147085-B1 | SUBSTITUTED TRANS-1.2-DIAMINOCYCLOHEXYL AMIDE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1990-03-14 | — | — | EP | disclosed |
| US-4738981-A | ANALGESICS | WARNER-LAMBERT (US) | 1988-04-19 | — | — | US | disclosed |
| US-4656182-A | ANALGESICS, DIURETICS, PSYCHOTHERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0147085-A2 | Substituted trans-1.2-diaminocyclohexyl amide compounds | WARNER-LAMBERT COMPANY (US) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012500-A1 | ORGANIC COMPOUNDS | OR10J3, REN, CACNA1E | KDM4E 2779/4885MAPT 2151/4885ALDH1A1 1317/4885 |
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | KDM4E 1204/4885MAPT 3557/4885ALDH1A1 2549/4885 |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | KDM4E 4481/4885MAPT 4731/4885ALDH1A1 2535/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | KDM4E 4481/4885MAPT 4731/4885ALDH1A1 2535/4885 |
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | SCNN1B, SCNN1A, SCNN1G | KDM4E 2621/4885MAPT 3437/4885ALDH1A1 2199/4885 |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | KDM4E 2621/4885MAPT 3437/4885ALDH1A1 2199/4885 |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | KDM4E 4481/4885MAPT 4731/4885ALDH1A1 2535/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | KDM4E 4481/4885MAPT 4731/4885ALDH1A1 2535/4885 |
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | KDM4E 2779/4885MAPT 2151/4885ALDH1A1 1317/4885 |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | KDM4E 4481/4885MAPT 4731/4885ALDH1A1 2535/4885 |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | KDM4E 2621/4885MAPT 3437/4885ALDH1A1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.